Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Drivers of AR indifferent anti-androgen resistance in prostate cancer cells.

Journal article

Handle F. et al, (2019), Sci Rep, 9

A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.

Journal article

Warren AY. et al, (2019), Oncogene, 38, 1136 - 1150

Putting Prostate Cancer Metabolism into the Right Context

Journal article

Mills IG., (2019), European Urology Oncology, 2, 37 - 38

IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling.

Journal article

Sheng X. et al, (2019), Nat Commun, 10

Expanding the potential for epigenetic therapies in combination with current standard-of-care therapy for prostate cancer

Conference paper

Manley J. et al, (2018), EUROPEAN JOURNAL OF CANCER, 103, E118 - E119

Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.

Journal article

Carabet LA. et al, (2018), Eur J Med Chem, 160, 108 - 119

The impact of transcription on metabolism in prostate and breast cancers.

Journal article

Poulose N. et al, (2018), Endocr Relat Cancer, 25, R435 - R452

Load More